Accelmed Partners Acquires Bioventus' Bioness Advanced Rehabilitation Business

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.

Bioness Medical Acquires Assets and Business of Harmonic Bionics

June 18, 2025

Medical Devices

Bioness Medical, a neuro-rehabilitation technology company based in Valencia, California, has acquired the assets and business of Austin, Texas–based Harmonic Bionics, a developer of a bilateral upper-extremity robotic exoskeleton. The acquisition expands Bioness's product portfolio into upper-extremity robotics and will complement its existing gait and balance systems once regulatory clearance for the Harmonic device is obtained.

Bioventus Inc. Acquires Misonix, Inc.

July 29, 2021

Medical Devices

Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.

Bioventus Acquires CartiHeal for $500M

August 30, 2021

Medical Devices

Nasdaq-traded Bioventus has elected to exercise its option to acquire Israel-based medical device company CartiHeal following FDA approval of the Agili-C implant, in a deal valued at approximately $500 million. Bioventus plans to work with the CartiHeal team on commercialization and reimbursement activities to bring Agili-C to market.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Concord Health Partners Leads Growth Financing in Accelus

May 29, 2025

Medical Devices

Accelus, a Palm Beach Gardens-based medical technology company specializing in expandable spinal implant technologies, closed a new equity financing round led by healthcare-focused investment firm Concord Health Partners. The capital will support Accelus's U.S. commercial expansion and further development of its spinal implant product pipeline.